NanoVibronix
NAOV

$0.7109

1.89%

Market Cap: $1.98M

About: NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Employees: 12

Healthcare Orthopedic, Prosthetic & Surgical Appliances & Supplies

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

9.34% less ownership

Funds ownership: 17.74% [Q1] → 8.39% (-9.34%) [Q2]

20% less funds holding

Funds holding: 10 [Q1] → 8 (-2) [Q2]

50% less capital invested

Capital invested by funds: $327K [Q1] → $163K (-$164K) [Q2]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NAOV.

See Analyst Rankings

Financial journalist opinion

NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the second quarter financials and recent business developments. To Our Shareholders: We are committed to our strategic vision of developing, improving and commerciali.

NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders

NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The “pilot” phase of the study is the first component of the broader study. As previously announced on November 28, 2023, the company signed a Research Agree.

NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan

NanoVibronix Issues Letter to Stockholders

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments. To Our Stockholders: We are committed to our strategic vision of developing, improving and commercializing o.

NanoVibronix Issues Letter to Stockholders

NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with CB Medical, LLC (“CB Medical”) for the sale and distribution of the Company's UroShield. UroShield is an ultrasound-based product designed to prevent bacterial colonization a.

NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield

NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs' FSS Contract Award

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective May 1, 2024, the Company's PainShield product will be included in the U.S. Department of Veteran Affairs' (“VA”) Federal Supply Schedule (“FSS”), a program that supports the healthcare acquisition needs of the VA.

NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs' FSS Contract Award

NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024

1x1 Meetings on Thursday, May 2, 2024 ELMSFORD, NY / ACCESSWIRE / April 24, 2024 / NanoVibronix, Inc. (Nasdaq:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 9:30 AM (Pacific Time). Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. will be hosting the presentation and answering questions at the conclusion.

NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024

NanoVibronix Issues Letter to Stockholders

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV)(“NanoVibronix”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the fourth quarter and full year 2023 and recent business developments. To Our Shareholders: We are committed to our strategic vision of developing, impr.

NanoVibronix Issues Letter to Stockholders

NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. (“Veranex”) to assist with the development of the company's next generation UroShield and PainShield products. Under the terms of the agreement, Veranex will provide certain re.

NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield

NanoVibronix Featured in Your Bladder Health Magazine

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield is featured in Issue 103 of Your Bladder Health Magazine in an article titled ‘UroShield Prevention is better than cure.' The article highlights the effectiveness of using UroShield in the prevention of catheter associated urinary tract infec.

NanoVibronix Featured in Your Bladder Health Magazine

NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the “LOI”) with APOGEPHA Arzneimittel GmbH (“APOGEPHA”) in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix's premiere UroShield product in Germany and other European m.

NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity

See News Rankings